Increased Anisotropy in Subcortical Gray Matter Structures: A Neurodegeneration Marker in Multiple Sclerosis.

MRI Evidence That Gadolinium-Enhancing Lesions Seen Twelve Weeks After Commencing Rituximab Treatment Are Associated with Lower Blood-Brain-Barrier Disruption Than Those Seen Prior to Treatment in Patients with Relapsing-Remitting Multiple Sclerosis

Multiple Sclerosis Lesions at 3T. Scalars and Fibers.

Myelin Sensitive Multi-Component DESPOT Imaging in Multiple Sclerosis